The Sanford Project: T-Rex Study, a Phase 2 clinical trial conducted collaboratively by Sanford Health and Caladrius Biosciences, Inc., (Caladrius)(Nasdaq: CLBS), has reached the halfway point for enrollment and treatment.
The project is studying the potential of CLBS03, Caladrius’ cell therapy consisting of each patient’s own regulatory T cells, or Tregs, to help the body fight type 1 diabetes. So far, 56 of a planned 111 participants have been treated. An interim analysis of early therapeutic effect will occur after the six-month post-treatment follow-up visit of the first 56 subjects, with results expected to be announced in late 2017 or early 2018. (read more)
Diabetes is a condition caused by a lack of insulin, which is a hormone made by your pancreas. Insulin acts like a key to open the doors into your cells, letting in sugar (glucose). In diabetes, the pancreas makes too little insulin to enable all the sugar in your blood to get into your muscles and other cells to produce energy.
If sugar can’t get into the cells to be used, it builds up in the bloodstream. Therefore, diabetes is characterised by high blood sugar (glucose) levels and is caused by the body’s inability to move glucose from the bloodstream into cells, resulting in high blood glucose levels. (read more)
Scientists have discovered a new way to treat diabetes.
Researchers from the University of Aberdeen Rowett Institute, in collaboration with teams from the Universities of Cambridge and Michigan, have identified that the medication Lorcaserin helps to improve Type 2 diabetes.
The medication modifies activity of neurons in the brain that are essential to regulate blood glucose levels.
It’s prescribed to help patients lose weight by regulating how hungry the person feels, but researchers have also discovered that the drug can reduce glucose levels and increase the body’s cells sensitivity to insulin. (read more)